Announcements Trials

Browse Landscape

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Leukemia, Myeloid, Acute 95 Myelodysplastic Syndromes 26 Recurrence 25 Lymphoma, Non-Hodgkin 24 Neoplasms 21 Leukemia, Lymphocytic, Chronic, B-Cell 19 Lymphoma, Large B-Cell, Diffuse 15 Leukemia 12 Lymphoma, Follicular 10 Multiple Myeloma 9 Hematologic Neoplasms 9 Lymphoma, B-Cell, Marginal Zone 8 Burkitt Lymphoma 7 Lymphoma, Mantle-Cell 6 Lymphoma, B-Cell 6 Lymphoma 6 Leukemia, Myelomonocytic, Chronic 6 Leukemia, Myeloid 6 Precursor Cell Lymphoblastic Leukemia-Lymphoma 5 Neoplasm Metastasis 4 Myeloproliferative Disorders 4 Leukemia, Biphenotypic, Acute 4 Small Cell Lung Carcinoma 3 Prostatic Neoplasms 3 GATA2 Deficiency 3 Carcinoma, Non-Small-Cell Lung 3 Breast Neoplasms 3 Primary Myelofibrosis 2 Immunoglobulin Light-chain Amyloidosis 2 Colorectal Neoplasms 2

Interventions

venetoclax 1 palbociclib 1 Letrozole 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1 × Breast Neoplasm Female × venetoclax × Clear all

NCT03900884 2024-11-07

PALVEN

Peter MacCallum Cancer Centre, Australia

Phase 1 Active not recruiting

Breast Neoplasm Female

Data powered by HemOnc (CC BY 4.0) Colophon ⚡